Comparative study of some energetic and steric parameters of the wild type and mutants HIV-1 protease: A way to explain the viral resistance

Journal of Cellular and Molecular Medicine

Volumn 6, Issue 2, 2002, Pages 251-260

  Avram, Speranta ^a   Movileanu, L ^b   Mihailescu, D ^a   Flonta, Maria Luiza ^a  

^a UNIVERSITY OF BUCHAREST   (Romania)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

Complex representation; Genetic code; Genomic signals; Genomics; Phase analysis; Sequence path; Unwrapped phase

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

PROTEINASE;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; COMPARATIVE STUDY; ELECTRICITY; ENZYMOLOGY; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; POINT MUTATION; PROTEIN SECONDARY STRUCTURE; STRUCTURE ACTIVITY RELATION;

AMINO ACID SUBSTITUTION; BINDING SITES; DRUG RESISTANCE, MICROBIAL; ELECTROSTATICS; HIV PROTEASE; HIV-1; HUMANS; MODELS, MOLECULAR; POINT MUTATION; PROTEIN STRUCTURE, SECONDARY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0036550078     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2002.tb00192.x     Document Type: Article

References (38)

1. Wu J., Adomat J.M., Ridky T.W., Louis J.M., Leis J., Harrison R.W., Weber I.T., Structural basis for specifity of retroviral proteases, Biochemistry, 37: 4518, 1998
2. Klabe R.M., Bacheler L.T., Ala P.J., Erickson-Viitanen S., Meek J.L., Resistance to HIV1 protease inhibitors: a comparison of enzyme inhibition and antiviral potency, Biochemistry, 37: 8735, 1998
3. Lappato R., Blundell T., Hemmings A., Overington J., Wilderspin A., X-ray analysis of HIV-1 proteinase at 2.7 Å resolution confirms structural homology among retroviral enzymes, Nature, 324: 299, 1989
4. Navia M.A., Fitzgerald P.M., McKeever B.M., Leu C.T., Heimbach J.C., Three- dimensional structure of aspartyl protease from Human Immunodeficiency Virus HIV-1, Nature, 337: 615, 1989
5. Woldawer A., Miller M., Jaskolski M., Sathyanarayana B.K., Baldwin E., Conserved folding in retroviral protease: crystal structure of a synthetic HIV-1 protease, Science, 245: 611, 1989
6. Wlodawer A., Vondrasek J., Inhibitors of HIV1 protease: a major success of structure-assisted drug design, Annu. Rev. Biophys. Struct., 27: 249, 1998
7. Piana S., Carloni P., Conformational flexibility of the catalytic Asp dyad in HIV-1 protease: an ab initio study on the free enzyme, Proteins: Struct., Funct., and Genet., 39: 26, 2000
8. Short G.F., Laikhter L.A., Lodder M., Shayo Y., Arslan T., Hecht M.S., Probing the S1/S1' substrate binding pocket geometry of HIV-1 protease with modified aspartic acid analogues, Biochemstry, 39: 8768, 2000
9. Chatfiel D.C., Eurenius K.P., Brooks R.R., HIV-1 protease cleavage mechanism: a theoretical investigation based on classical MD simulation and reaction patch calculations using a hybrid QM/MM potential, Theochem. J. Mol. Struct., 423: 79, 1998
10. Ala P.J., Huston E.E., Klabe R.M., Jadhav K.P., Lam P.Y.S., Chang-Hwan C., Counteracting HIV1-protease drug resistance: structural analysis of mutant protease complex with XV638 and SD146 cyclic urea amides with broad specifies, Biochemistry, 36: 1573, 1998
11. Rose R.B., Craick C.S., Stroud R.M., Domain flexibility in retroviral proteases: structural implication for drug resistant mutations, Biochemistry, 37: 2607, 1998
12. Nair A.C., Miertus S., Tossi A., Romeo D., A computational study of the resistance of HIV-1 aspartic protease to the inhibitors ABT-538 and VX-478 and design of new analogues, Biochem. Biophys. Res. Commun., 242: 545, 1998
13. Markland W, Rao BG, Parsons JD, Black J, Zuchowski L, Tisdale M., Structural and kinetic analyses of the protease from an amprenavir-resistant human immunodeficiency virus type 1 mutant rendered resistant to saquinavir and resensitised to amprenavir, J. Virol., 74: 4710, 2000
14. Sansom C.E., Wu J., Weber I.T., Molecular mechanism analysis of inhibitor binding to HIV1 protease, Protein. Eng., 5: 659, 2000
15. Rarey M., Kramer B., Lengauer T., The particle concept: placing discrete water molecules during protein-ligand docking predictions, Proteins, 34: 17, 1999
16. Ferguson D.M., Radmer R.J., Kollman P.A., Determination of the relative binding free energies of pepetide inhibitors to the HIV-1 protease, J. Med Chem., 34: 2654, 1991
17. Rick S.W., Ericson J.W., Burt S.K., Reaction path and free energy calculation of the tranzition between alternate conformations of HIV-1 protease, Proteins: Struct. Funct. and Genet., 32: 7, 1998
18. David L., Luo R., Gilson K.G., Comparison of generalized born and Poisson models: energetic and dynamics of HIV protease. J. Comp. Chem., 21: 295, 2000
19. Chun M., MBO(N)D: A multibody method for long-time molecular dynamics simulations, J. Comp. Chem., 21: 159, 2000
20. Waller L.C., Oprea T.I., Giolitti A., Marshall R.G., Three-dimensional QSAR of Human Immunodeficiency Virus (I) protease inhibitors. 1. A CoMFA study employing experimentally - determined alignment rules, J. Med. Chem., 36: 4152, 1993
21. Oprea T.I., Waller L.C., Marshall R.G., Three-dimensional QSAR of Human Immunodeficiency Virus (I) protease inhibitors. 2. Predictive power using limited exploration of alternate binding modes, J. Med. Chem., 37: 2206, 1994
22. Oprea T.I., Waller L.C., Theoretical and practical aspects of three-dimensional qualitative structure-activity relationships, J. Comp. Chem., 11: 127, 1997
23. Gupta S.P., Babu M.S., Kaw N., Quantitative structure-active relationships of some HIV-protease inhibitors, J. Enz. Inhib., 14: 109, 1999
24. Gupta S.P., Babu M.S., Garg R., Sowmya S., Quantitative structure-activity relationships studies on cyclic cyanoguanidine acting as HIV-1 protease inhibitors, Bioorganic and Medical Chemistry, 7: 407, 1999
25. Norinder U., Refinement of Catalyst hypotheses using simplex optimization, J. Comp. Aided. Mol. Des., 14: 545, 2000
26. Luque I., Todd M.J., Gómez J., Semo N., Freire E., Molecular basis of resistance to HIV-1 protease inhibition: a plausible hypothesis, Biochemistry; 37: 5791, 1998
27. Connolly M.L., Analytical molecular surface calculation, J. Appl. Cryst., 16: 548, 1983
28. Ponder J.W., Richards F.M., An efficient Newton-like method for molecular mechanics energy minimization of large molecules, J. Comput. Chem., 8: 1016, 1987
29. Dudek M., Ramnarayan K., Ponder J. W., Protein structure prediction using a combination of sequence homology and global energy minimization II. Energy functions, J. Comput. Chem., 19:548, 1998
30. Abagyan R.A., Totrov, M.M., Kuznetsov D.N., ICM - a new method for protein modeling and design. Applications to docking and structure prediction from the distorted native conformation, J. Comp. Chem., 15: 488, 1994
31. Yu J., Abagyan R., Dong S., Gilbert A., Nusenzweig V., Tomlinson, S., Mapping of the active site of CD59, J. Expt. Medicine, 185: 745, 1997
32. Brooks B.R., Bruccoleri R.E., Olafson B.D., States D.J., Swaminathan S., Karplus M., CHARMM, A program for macromolecular energy, minimization, and dynamics calculations, J. Comp. Chem., 4: 187, 1983
33. Lam P.Y., Ru Y., Jadhav P.K., Aldrich P.E., DeLucca G.V., Eyermann C.J., Chang C.H., Emmett G., Holler E.R., Daneker W.F., Li. L., Confalone P.N., McHugh R.J., Han Q., Li R., Markwalder J.A., Seitz S.P., Sharpe T.R., Bacheler L.T., Rayner M.M., Klabe R.M., Shum L., Winslow D.L., Kornhauser D.M., Hodge C.N., Cyclic HIV protease inhibitors: synthesis, conformational analysis, P2/P2' structure-activity relationship, and molecular recognition of cyclic ureas, J. Med. Chem., 30: 3514, 1996
34. HyperChem Computational Chemistry Manual (version 5) available from Hypercube, Inc. 1115 NW 4th Street, Gainesville, FL 32601 USA, 2001
35. Schaal W., Karlsson A., Ahlsen G., Lindberg J., Andersson H.O., Danielson U.H., Classon B., Unge T., Samuelsson B., Hulten J., Hallberg A., Karlen A., Synthesis and comparative molecular field analysis (CoMFA) of symmetric and nonsymmetric cyclic sulfamide HIV-1 protease inhibitors, J. Med. Chem., 44: 155, 2001
36. Molla A., Korneyeva M., Gao Q., Vasavanonda S., Schipper P.J., Mo H.M., Markowitz M., Chernyavskiy T., Niu P., Lyons N., Hsu A., Granneman G.R., Ho D.D., Boucher C.A., Leonard J.M., Norbeck D.W., Kempf D.J., Ordered accumulation of mutations in HIV protease confers resistance to ritonavir, Nat. Med., 2: 760, 1996
37. Pati S., Pelser C.B., Dufraine J., Bryant J.L., Reitz M.S., Weichold F.F., Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma, Blood, 99: 3771, 2002.
38. Akeb F., Ferrua B., Creminon C., Roptin C., Grassi J., Nevers M.C., Guedj R., Garraffo R., Duval D., Quantification of plasma and intracellular levels of the HIV protease inhibitor ritonavir by competitive ELISA, J. Immunol. Methods., 263: 1, 2002